Perico Maria Elisa, Grasso Silvia, Brunelli Matteo, Martignoni Guido, Munari Enrico, Moiso Enrico, Fracasso Giulio, Cestari Tiziana, Naim Hassan Y, Bronte Vincenzo, Colombatti Marco, Ramarli Dunia
Department of Pathology and Diagnostics, Section of Immunology, University of Verona, Verona, Italy.
Current address: Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Oncotarget. 2016 Nov 8;7(45):74189-74202. doi: 10.18632/oncotarget.12404.
The expression of Prostate Specific-Membrane Antigen (PSMA) increases in high-grade prostate carcinoma envisaging a role in growth and progression. We show here that clustering PSMA at LNCaP or PC3-PSMA cell membrane activates AKT and MAPK pathways thus promoting proliferation and survival. PSMA activity was dependent on the assembly of a macromolecular complex including filamin A, beta1 integrin, p130CAS, c-Src and EGFR. Within this complex beta1 integrin became activated thereby inducing a c-Src-dependent EGFR phosphorylation at Y1086 and Y1173 EGF-independent residues. Silencing or blocking experiments with drugs demonstrated that all the complex components were required for full PSMA-dependent promotion of cell growth and/or survival in 3D culture, but that p130CAS and EGFR exerted a major role. All PSMA complex components were found assembled in multiple samples of two high-grade prostate carcinomas and associated with EGFR phosphorylation at Y1086. The expression of p130CAS and pEGFRY1086 was thus analysed by tissue micro array in 16 castration-resistant prostate carcinomas selected from 309 carcinomas and stratified from GS 3+4 to GS 5+5. Patients with Gleason Score ≤5 resulted negative whereas those with GS≥5 expressed p130CAS and pEGFRY1086 in 75% and 60% of the cases, respectively.Collectively, our results demonstrate for the first time that PSMA recruits a functionally active complex which is present in high-grade patients. In addition, two components of this complex, p130CAS and the novel pEGFRY1086, correlate with progression in castration-resistant patients and could be therefore useful in therapeutic or surveillance strategies of these patients.
前列腺特异性膜抗原(PSMA)在高级别前列腺癌中的表达增加,提示其在肿瘤生长和进展中发挥作用。我们在此表明,将PSMA聚集在LNCaP或PC3-PSMA细胞膜上可激活AKT和MAPK信号通路,从而促进细胞增殖和存活。PSMA的活性依赖于一种大分子复合物的组装,该复合物包括细丝蛋白A、β1整合素、p130CAS、c-Src和表皮生长因子受体(EGFR)。在这个复合物中,β1整合素被激活,从而在不依赖表皮生长因子(EGF)的Y1086和Y1173位点诱导c-Src依赖的EGFR磷酸化。药物沉默或阻断实验表明,在三维培养中,所有复合物成分都是PSMA依赖的细胞生长和/或存活促进作用所必需的,但p130CAS和EGFR发挥主要作用。在两个高级别前列腺癌的多个样本中发现所有PSMA复合物成分都组装在一起,并与Y1086位点的EGFR磷酸化相关。因此,通过组织芯片分析了从309例前列腺癌中选出的16例去势抵抗性前列腺癌中p130CAS和pEGFRY1086的表达,并根据Gleason评分从3+4分层到5+5。Gleason评分≤5的患者结果为阴性,而Gleason评分≥5的患者中,分别有75%和60%的病例表达p130CAS和pEGFRY1086。总体而言,我们的结果首次证明PSMA招募了一种在高级别患者中存在的功能活性复合物。此外,该复合物的两个成分p130CAS和新发现的pEGFRY1086与去势抵抗性患者的疾病进展相关,因此可能有助于这些患者的治疗或监测策略。